Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S0025: Irinotecan in Refractory Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00053833Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2003
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of irinotecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by SWOG Cancer Research Network. Started Apr 2003; status: terminated.
02
Drugs
irinotecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00053833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053833.